Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Arvinas' Veppanu (vepdegestrant) receives first-ever FDA approval for estrogen receptor-positive, HER2-negative metastatic breast cancer with ESR1 mutations
Small molecule, cancer, PROTAC, breast cancer, ESR1 mutation, estrogen receptor degrader - Read more

UCB acquires IMIDomics' patient insights business to advance precision medicine in inflammatory diseases
Acquisition, autoimmune, data analytics, precision medicine, multi-omics - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Corcept Therapeutics' dazucorilant linked to 87% death risk reduction in Ph2 amyotrophic lateral sclerosis study ahead of Ph3
Small molecule, neurological, cortisol modulator, ALS, survival benefit - Read more

Everads Therapy publishes Ph1 first-in-human data for Everads Injector in diabetic macular edema
Small molecule, ophthalmology, drug delivery, diabetic macular edema, suprachoroidal injection, triamcinolone acetonide - Read more

Restore Vision's RV-001 shows Ph1/2 interim vision gains in advanced retinitis pigmentosa patients via GPCR optogenetic gene therapy
Gene therapy, neurological, AAV vector, optogenetics, retinitis pigmentosa, GPCR - Read more

Celcuity's (gedatolisib) Ph3 trial meets primary endpoint in PIK3CA mutant hormone receptor-positive, HER2-negative advanced breast cancer
Small molecule, cancer, PI3K/AKT/mTOR pathway, breast cancer, PIK3CA mutation, combination therapy - Read more

Moderna Q1 revenue triples to $389M, driven by international COVID-19 vaccine sales
mRNA vaccine, infectious disease, financial, revenue impact - Read more

Amgen Q1 revenue rises 6% to $8.6B as Repatha's 34% sales surge offsets Prolia biosimilar losses
Monoclonal antibody, cardiovascular, revenue impact, competitive - Read more

Hemab Therapeutics prices upsized $301.5M IPO, developing blood coagulation disorder therapies
Hematology, blood coagulation, clinical-stage, rare disease - Read more

Seaport Therapeutics prices upsized $254.9M IPO for neuropsychiatric medicine development
Neuropsychiatric, clinical-stage, small molecule - Read more

Stoked Bio closes Seed round, advancing anti-infectives and cancer therapeutics pipeline
Anti-infectives, oncology, AI-driven, small molecule, neurological, infectious disease - Read more

Novo Nordisk retires Rybelsus brand, rebrands oral semaglutide tablet as "Ozempic pill" in US
Small molecule, type 2 diabetes, strategic, competitive, brand marketing - Read more

Esperion to go private in $1.1B deal with investment firm ARCHIMED, shareholders receive 58% premium
Small molecule, cardiovascular, strategic, major transaction - Read more

UCB to acquire Candid Therapeutics for $2.2B, expanding T-cell engager pipeline for autoimmune diseases
T-cell engager, autoimmune, strategic, major transaction - Read more

FDA names Katherine Szarama as acting CBER director following Vinay Prasad's departure
Gene therapy, rare disease, regulatory, operational - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Ligand Pharmaceuticals terminates TRβ program licenses with Viking Therapeutics, alleging contract breach
Licensing deal, small molecule, metabolic disease, royalties, contract dispute - Read more

Amgen drops (adezkibart) for Sjögren's syndrome, (anvumetostat) for cancer after Ph2 futility failures
Small molecule, antibody, cancer, autoimmune, Sjögren's syndrome, lung cancer - Read more

Summit Therapeutics' ivonescimab (ivonescimab) Ph3 interim progression-free survival analysis misses bar in squamous non-small-cell lung cancer
Small molecule, cancer, antibody, non-small cell lung cancer, PD-1/VEGF bispecific, combination therapy - Read more

Bristol Myers Squibb's Krazati (adagrasib) faces colorectal cancer approval setback after Ph3 KRAS inhibitor trial failure
Small molecule, cancer, KRAS inhibitor, colorectal cancer, non-small cell lung cancer - Read more

J&J discontinues Ph1 JNJ-4496 (dual CD19/CD20 CAR-T) and JNJ-9530 programs for large B-cell lymphoma
Cell therapy, cancer, CAR-T, non-Hodgkin lymphoma, CD19, CD20 - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here